Peptide related to human programmed cell death and DNA encoding the same

• US 5,698,520 A
• Filed: 12/18/1996
• Issued: 12/16/1997
• Est. Priority Date: 03/01/1994
• Status: Expired due to Term

• Current Assignee: ONO Pharmaceutical Company Limited, Tasuku Honjo
• Original Assignee: ONO Pharmaceutical Company Limited, Tasuku Honjo
• Inventors: Shinohara, Takashi, Honjo, Tasuku, Ishida, Yasumasa
• Primary Examiner(s): Prouty, Rebecca E.
• Assistant Examiner(s): Bugaisky, Gabriele E.
• Application Number:
  US08/768,626
• Time in Patent Office: 363 Days
• Field of Search: 530/350, 530/395, 514/12, 514/8, 424/185.1
• US Class Current: 514/18.9
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/70503 Immunoglobulin superfamily
• CPC Class Codes: C07K 2319/00 Fusion polypeptide

Abstract

A membrane protein related to human programmed cell death (PD-1) and DNA encoding the said protein is provided. PD-1 protein may be useful for the treatment of various infections, immunological depression or acceleration, or tumors etc.

Claims

1. A polypeptide having the amino acid sequence shown in SEQ ID NO:

1.

2. A pharmaceutical composition containing a polypeptide according to claim 1 in association with a pharmaceutically acceptable diluent and/or carrier.

3. A substantially pure polypeptide having the amino acid sequence shown in SEQ ID NO:

1.

4. A pharmaceutical composition comprising a polypeptide according to claim 3, and a pharmaceutically acceptable diluent and/or carrier.